Pα+ Psychedelic Bulletin #159: Patient Access to MDMA-Assisted Therapy; Notes from SXSW; Whole Mushroom vs. Synthetic Psilocybin Post published:March 21, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #158: Fluence Brings Psychedelic Therapy Training to Ukraine; MindBio’s Microdosing Readout; Biomind’s 5-MeO-DMT Study; and more… Post published:March 6, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #157: Psilocybin for Generalised Anxiety Disorder; Uptick in Psilocybin-Related Poison Centre Calls Post published:March 1, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass Post published:February 19, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #155: MAPS Invests in Numinus, Hopes to Offer Experiential Training for MDMA Therapists Post published:February 8, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #154: Public & Industry Respond to DEA’s Renewed DOI and DOC Scheduling Plan; TARA Mind Scores $8m Seed; Updates on State Psychedelics Programs Post published:January 26, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #153: MindMed Scraps Microdosing Program; Eagerly Anticipated Ibogaine Study Publishes; Compass Collaborates with Greenbrook; Gilgamesh’s GM-1020 Readout; and more… Post published:January 12, 2024 Post category:Psychedelic Bulletin/Pα+
Psychedelic Bulletin #152: Policy and Business Updates Post published:December 22, 2023 Post category:Psychedelic Bulletin
Pα+ Psychedelic Bulletin #151: Psilocybin for BDII, ACNP Readouts, Methylone for PTSD, and More Psychedelic Drug Dev. News Post published:December 14, 2023 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #150: Drug Development and Research Updates Post published:November 29, 2023 Post category:Psychedelic Bulletin/Pα+